Azora Therapeutics Inc(AZR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -16.54 | Insider Own | 9.2% | Shs Outstand | 2.6M | Perf Week | -2.81% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 76.54% | Insider Trans | 19.84% | Shs Float | 2.4M | Perf Month | -7.75% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.17 | Inst Own | 19.41% | Short Float | 7.54% | Perf Quarter | 4.67% |
| Income | -0.06B | P/S | - | EPS this Y | 78.21% | Inst Trans | -11.91% | Short Ratio | 3.11 | Perf Half Y | 145.81% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 61.9% | ROA | -322.1% | Short Interest | 0.18M | Perf YTD | -30.73% |
| Book/sh | -14.61 | P/C | 0.35 | EPS past 3/5Y | 88.55% 53.46% | ROE | -265.94% | 52W High | -58.69% ($9.22) | Perf Year | -57.28% |
| Cash/sh | 10.94 | P/FCF | - | Sales past 3/5Y | - | ROIC | -241.16% | 52W Low | 190.84% ($1.31) | Perf 3Y | -92.18% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.78% | Gross Margin | - | Volatility(W/M) | 30.54% 15.91% | Perf 5Y | -99.81% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.65 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.63 | EPS Q/Q | -144.05% | Profit Margin | - | RSI (14) | 46.48 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.63 | Sales Q/Q | - | SMA20 | -1.59% ($3.87) | Beta | 1.65 | Target Price | $8.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/17 | SMA50 | -18.74% ($4.69) | Rel Volume | 2.93 | Prev Close | $4.88 |
| Employees | 6 | LT Debt/Eq | - | EPS/Sales Surpr. | -989.59% - | SMA200 | 18.17% ($3.22) | Avg Volume(3M) | 0.06M | Price | $3.81 |
| IPO | 2018/7/27 | Option/Short | No/Yes | Trades | 1513 | Volume | 169,254 | Change | -21.93% |
AZRAzora Therapeutics Inc | NASD | Biotechnology 🧬 A US Nasdaq-listed biotech company developing AT177, a therapeutic candidate for ulcerative colitis. It aims to improve the safety of inflammatory bowel disease treatment with an oral small molecule compound designed to act only within the intestinal tract. As an early-stage clinical company with no revenue, pipeline progress is the core driver of its enterprise value.
Over the past 1 year, roughly in the middle
59% below its 1-year high.
Traded more than usual. That is 293% of its average volume.
AZR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +78.2% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.4%.
Tap to view numbers
It ranks #503 of 597 in the industry
Based on market cap of $10M.
AZR#503 Azora Therapeutics Inc $10M PER - 
PHIO#504 Phio Pharmaceuticals Corp $10M PER - 
CALC#505 CalciMedica Inc $10M PER - 
BLRX#506 Bioline Rx Ltd ADR $10M PER - 
TPST#506 Tempest Therapeutics Inc $10M PER - 
FAQ
What kind of company is AZR?
AZR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AZR?
The market cap of AZR is approximately $10M, ranking 5,431 within its sector.
What is the 52-week high and low for AZR?
AZR has recorded a 52-week high of $9.22 and a low of $1.31.
